Mounjaro® (tirzepatide) prescription available online

It is essential to know that Mounjaro® is only FDA-approved to treat type 2 diabetes and lower A1c levels. However, Zepbound® is the new version of tirzepatide FDA-approved for weight loss.

If you have type 2 diabetes, a BMI of at least 27, and are struggling with weight loss, speak to a board-certified doctor to begin the evaluation process and complete any necessary lab tests. Book an online appointment with one of our board-certified doctors to discuss if you can qualify for Mounjaro® and begin the evaluation process.

Mounjaro® is a new type 2 diabetes drug that can also help with weight loss. If you have diabetes and are struggling with weight loss, speak with one of our trusted, board-certified physicians online to discuss your health concerns and start the evaluation process for Mounjaro®. This would include discussing your medical history and current medication and ordering baseline tests and studies to determine if you qualify for a Mounjaro® prescription.

Wegovy® and Saxenda® are type 2 diabetes medications that are extremely effective for weight loss. They have now been approved for weight loss only without type 2 diabetes. Speak to one of our trusted, board-certified doctors about how Wegovy® and Saxenda® could be right for you.

You may be able to get a Mounjaro® prescription online after meeting with a doctor to discuss your medical history and completing any necessary evaluations.

You can been the evaluation process for Mounjaro® online with one of our board-certified doctors. If you have diabetes and are looking for weight management options, book an appointment with one our our top rated doctors online. After ordering any necessary lab tests and reviewing your results, if you qualify, your doctor can electronically send a prescription to your local pharmacy.

Although Mounjaro® is only approved to treat type 2 diabetes, Mounjaro® can help promote weight loss by reducing hunger and slowing digestion.

Although Mounjaro® can promote weight loss, it has only been FDA-approved to treat type 2 diabetes.

Tirzepatide is what is known as a “dual glucose-dependent insulinotropic polypeptide–GLP-1 receptor agonist.”  This long and complicated name means it can do two things:

1. Stimulate GLP-1 receptors in the body to both help control blood sugar and reduce hunger, promoting weight loss.

2. Promote release of glucose-dependent insulinotropic polypeptide which helps modulate levels of a hormone called glucagon and improve insulin sensitivity of adipose (fat) tissue.

Mounjaro® and Ozempic® are in the same class of drugs, but work via different mechanisms. Mounjaro® works on GIP and GLP-1 receptors, while Ozempic® only works on GLP-1 receptors. Both are used to treat type 2 diabetes and can promote weight loss. To find out which one is right for you, speak to one of our board-certified doctors.

If you qualify for a Mounjaro® prescription and the drug is included in your insurance plan’s formulary, your monthly cost may vary.  Most branded type 2 diabetes and weight loss medications require prior authorization for insurance to cover the cost. Your PlushCare physician and care team will reach out to your insurer on your behalf, and this process can take several business days. If you are denied the prior authorization or do not have health insurance, you may still purchase the medication at the total cash price. It is important to note that a type 2 diabetes diagnosis is usually required for insurance approval of this medication.

The makers of tirzepatide/Mounjaro® (Lilly) are currently offering a co-pay savings card of $25 per month for specific individuals who qualify, which can be found on their website. Unfortunately, Mounjaro® is expensive without insurance, ranging around $1000/month, depending on the pharmacy.

A limited number of patients may be eligible for the Mounjaro® Saving Card, which allows certain patients to pay as little as $25 for a one-month or three-month supply of Mounjaro®. You will likely need a type 2 diabetes diagnosis for eligibility. To find out if you are eligible, complete the enrollment form on the Mounjaro® website.

Mounjaro® helps control blood sugar and reduce hunger by releasing more insulin, less sugar, and slowing down digestion. This helps treat diabetes and can promote weight loss.

Production and distribution of tirzepatide to pharmacies began in June 2022, but there is limited availability.

A study published in 2021 called SURPASS-2 on over 1800 participants found that Mounjaro® (tirzepatide) + metformin was superior to semaglutide +metformin on reduction in Hemoglobin A1C in individuals with Type 2 Diabetes.  When evaluating tirzepatide vs. semaglutide, as a secondary endpoint, 5.5% more weight loss was noted in the tirzepatide group compared to the semaglutide group.

The most recent clinical trial awaiting publication, called SURMOUNT-1, reports that the average weight loss among over 2500 trial participants was 16% at 72 weeks.  Adults who were randomly assigned to receive tirzepatide had average weight losses of 16% with 5 mg of the drug, 21.4% with 10 mg, and 22.5% with 15 mg, compared with only 2.4% weight loss with participants who took a placebo. Of the tirzepatide group, 89% achieved a weight loss of at least 5% compared with 28% in the placebo group as well. The average BMI of trial participants starting off was 38, and was reduced to an average of 30, with many subjects getting into the normal range.

The SURMOUNT-1 trial is still ongoing, and additional key outcome measures under study include progression to type 2 diabetes among patients with prediabetes.  It is anticipated that the trial will be continued for a total of an additional 104 weeks.

Keep in mind that currently Mounjaro® (tirzepatide) is not technically FDA-approved for weight loss, but to treat diabetes.  But based on the results of SURMOUNT-1, if Mounjaro® was approved for weight loss, it would easily become the most effective drug available. Given that it has two different mechanisms of action, it appears to have a greater effect on weight and blood sugar than GLP-1 agonist drugs alone, such as semaglutide or liraglutide, which are both currently FDA approved for sugar and weight control under different trade names. So when comparing tirzepatide vs. semaglutide, liraglutide, or other diabetes medicines, it seems to be much more effective.

Given that over half the patients on the 10 mg dose and 63% of those on the 15 mg dose lost more than 20% of their body weight, this number takes many past the weight loss achieved long term with surgical interventions such as the lap-band, and is within the typical ranges achieved long term with procedures such as the sleeve gastrectomy.